RJA
CLB icon

Raymond James & Associates’s Core Laboratories CLB Stock Holding History

Raymond James & Associates’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-33,270
Closed -$659K – 3975
2022
Q2 		$659K Sell
33,270
-29,319
-47% -$779K ﹤0.01% 2732
2022
Q1 		$1.98M Buy
+62,589
New +$1.75M ﹤0.01% 2142
2021
Q3 		– Sell
-11,206
Closed -$436K – 4138
2021
Q2 		$436K Buy
11,206
+1,044
+10% +$37.4K ﹤0.01% 3187
2021
Q1 		$293K Buy
+10,162
New +$347K ﹤0.01% 3371
2020
Q3 		– Sell
-12,462
Closed -$253K – 3597
2020
Q2 		$253K Sell
12,462
-27,688
-69% -$496K ﹤0.01% 3013
2020
Q1 		$415K Sell
40,150
-62,062
-61% -$1.74M ﹤0.01% 2547
2019
Q4 		$3.85M Sell
102,212
-20,261
-17% -$910K ﹤0.01% 1417
2019
Q3 		$5.71M Sell
122,473
-4,837
-4% -$225K 0.01% 1144
2019
Q2 		$6.66M Buy
127,310
+4,884
+4% +$286K 0.01% 1077
2019
Q1 		$8.44M Buy
122,426
+13,703
+13% +$919K 0.01% 898
2018
Q4 		$6.48M Sell
108,723
-57,994
-35% -$5M 0.01% 972
2018
Q3 		$19.3M Buy
166,717
+19,971
+14% +$2.25M 0.03% 538
2018
Q2 		$18.5M Buy
146,746
+15,915
+12% +$1.94M 0.03% 533
2018
Q1 		$14.2M Buy
130,831
+27,759
+27% +$3.07M 0.03% 604
2017
Q4 		$11.3M Sell
103,072
-469
-0.5% -$46.8K 0.02% 710
2017
Q3 		$10.2M Sell
103,541
-1,613
-2% -$156K 0.02% 719
2017
Q2 		$10.6M Buy
105,154
+19,423
+23% +$2.09M 0.02% 673
2017
Q1 		$9.9M Buy
85,731
+4,549
+6% +$529K 0.02% 677
2016
Q4 		$9.74M Sell
81,182
-13,527
-14% -$1.5M 0.02% 642
2016
Q3 		$10.6M Buy
94,709
+21,637
+30% +$2.49M 0.03% 573
2016
Q2 		$9.05M Buy
73,072
+2,766
+4% +$334K 0.03% 575
2016
Q1 		$7.9M Sell
70,306
-12,170
-15% -$1.26M 0.03% 605
2015
Q4 		$8.97M Buy
82,476
+63,369
+332% +$7.25M 0.03% 556
2015
Q3 		$1.91M Buy
19,107
+1,929
+11% +$210K 0.01% 1245
2015
Q2 		$1.96M Buy
17,178
+3,805
+28% +$461K 0.01% 1330
2015
Q1 		$1.4M Buy
+13,373
New +$1.42M 0.01% 1464

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Raymond James & Associates's CLB Position: Q3 2022 in Review

Raymond James & Associates sold out of Core Laboratories (CLB) in Q3 2022, closing a stake of 33,270 shares — an estimated $659K sold.

Raymond James & Associates first reported a position in CLB in Q1 2015 and held it in 26 quarters. The position peaked at $19.3M in Q3 2018. 162 funds tracked by Wall St. Rank hold CLB as of Q3 2022.

  • Raymond James & Associates reported no remaining Core Laboratories position as of Q3 2022 after selling out during the quarter.
  • Raymond James & Associates sold 33,270 Core Laboratories shares in Q3 2022, an estimated $659K.
  • Raymond James & Associates first reported a position in Core Laboratories in Q1 2015 and held it in 26 quarters.
  • Raymond James & Associates's Core Laboratories position peaked at $19.3M in Q3 2018.
  • 162 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2022.

Based on Raymond James & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.